T cell immunoglobulin mucin-4 (TIM-4) and TIM-3 monoclonal antibodies (mAbs) were specifically used by the authors to increase the therapeutic effects of immunisation against existing B16 murine melanomas. The gene discussed is TIMD4; the disease is melanoma.